M. Jeffrey, Josefin Bartholdson Scott, Shyamanova Mazumdar, Richard White, Ellen E. Higginson, Mailis Maes, Sally Forrest, Joana Pereira-Dias, Surendra Parmar, Emma Heasman-Hunt, Martin D. Curran, Petra Polgarova, J Herre, Els Wauters, Diether Lambrechts, Pierre Van Mol, Cato Jacobs, Joost Wauters, Emma E. Davenport, Stephen Baker, Gordon Dougan, Vilas Navapurkar, Andrew Conway Morris
Pneumonia is the leading infectious disease killer worldwide and commonly requires admission to critical care. Despite its prevalence, the underpinning biology of severe pneumonia remains incompletely understood. Here we perform multifaceted assessments of bronchoalveolar transcriptome, cytokines, microbiology, and clinical features to biologically characterise a cohort of patients with suspected severe pneumonia. Our data implicate three lung-restricted transcriptionally defined severe pneumonia endotypes (termed 'Pneumotypes' (Pn)). All three Pneumotypes have comparable clinical presentations and severity of respiratory failure but experience divergent outcomes. Pn1, the most common, is characterised by low alveolar cytokines, expanded tolerogenic macrophages and epithelial damage. Pn3 is characterised by immature neutrophil infiltration, IL-6-STAT3 activation and longer duration of mechanical ventilation. Pn2 displays the fastest resolution, exhibiting a balanced immune response and epithelial-endothelial repair signatures. We identify and validate mechanistically distinct phenotypes in the lungs of patients with suspected pneumonia and acute lung injury, implicating targets for personalised therapy.